Universal protection of allogeneic cell therapies from natural killer cells via CD300a agonism
S.-Q. Zhang, F. Thomas, J. Fang, K. Austgen, C. Cowan, G. G. Welstead
This paper develops CD300a TASR, an engineered ligand that universally protects HLA-deficient allogeneic T cells from NK cell rejection and enhances CAR-T efficacy.
bioRxiv · May 5, 2024Immunology